Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big ...

Ultraphonix, Rock of Ages). “When I wrote 'Stay' with George and Sahaj Ticotin, we were talking about the crazy punch-drunk love we have all experienced throughout our lives,” Leal explained of the ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Panasonic's Toughbook 40 Mk2 (starts at $4,699; about $6,375 as tested) is designed for calls from a speeding ambulance with sirens and shouting in the background. Rugged laptops work just fine ...

BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex’s experimental non-opioid pain medication “reaffirms our confidence in the strength of suzetrigine ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Google Cloud is enabling general availability for its Vertex AI platform in addition to new features for its Healthcare Data Engine (HDE), the company announced in a press release this morning.

Both Maschine MK1 and MK2 and Maschine Mikro MK1 and MK2 will be retired, and owners of these devices will not be able to update them with new Maschine software, or receive technical support, from ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.